Aclarion, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted (rNPV) DCF: 8% probability of commercial success (Nociscan achieving CPT reimbursement and broad clinical adoption) reaching 2% penetration of the company's cited $2B addressable market by year 8 ($40M revenue) at a 30% steady-state FCF margin ($12M FCF), capitalized at a 15x FCF terminal multiple ($180M enterprise value), discounted 8 years at a 30% risk-adjusted rate (present value $22.1M); blended with a 92% probability failure-case residual equity value of $3M; probability-weighted equity value of about $4.5M; divided by 2,882,371 shares outstanding as of the August 2026 10-Q.

Reasoning: Aclarion is a pre-revenue (FY2025 revenue of only $0.076M), single-product diagnostics company with binary reimbursement/clinical-adoption risk, no debt, no analyst coverage, and a demonstrated pattern of dilutive capital raises every few months, so a conventional near-term free-cash-flow DCF would be dominated by noise from continuous equity raises rather than fundamentals; a probability-weighted (risk-adjusted) NPV that separately values a plausible commercial-success scenario against a residual failure scenario is the standard approach used for early-stage medtech/biotech assets like this.